EGFR and non-small cell lung carcinoma: Despite the high response rates to various first- and second-generation EGFR-TKIs, eventually all patients with metastasized NSCLC with an EGFR mutation will develop disease progression due to acquired resistance, mostly attributable to the EGFR T790M mutation [4].